Sorbonne Université, INSERM, UMRS1158 Neurophysiologie Respiratoire Expérimentale et Clinique, F-75005, Paris, France
AP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Université, Service des Explorations Fonctionnelles de la Respiration, de l'Exercice et de la Dyspnée (Département R3S), F-75013, Paris, France.
Eur Respir Rev. 2021 Jan 6;30(159). doi: 10.1183/16000617.0187-2020. Print 2021 Mar 31.
Cardiopulmonary exercise testing (CPET) has long been used as diagnostic tool for cardiac diseases. During recent years CPET has been proven to be additionally useful for 1) distinguishing between normal and abnormal responses to exercise; 2) determining peak oxygen uptake and level of disability; 3) identifying factors contributing to dyspnoea and exercise limitation; 4) differentiating between ventilatory (respiratory mechanics and pulmonary gas exchange), cardiovascular, metabolic and peripheral muscle causes of exercise intolerance; 5) identifying anomalies of ventilatory (respiratory mechanics and pulmonary gas exchange), cardiovascular and metabolic systems, as well as peripheral muscle and psychological disorders; 6) screening for coexistent ischaemic heart disease, peripheral vascular disease and arterial hypoxaemia; 7) assisting in planning individualised exercise training; 8) generating prognostic information; and 9) objectively evaluating the impact of therapeutic interventions. As such, CPET is an essential part of patients' clinical assessment. This article belongs to the special series on the "Ventilatory efficiency and its clinical prognostic value in cardiorespiratory disorders", addressed to clinicians, physiologists and researchers, and aims at encouraging them to get acquainted with CPET in order to help and orient the clinical decision concerning individual patients.
心肺运动测试(CPET)长期以来一直被用作心脏病诊断工具。近年来,CPET 已被证明对以下方面具有额外的作用:1)区分正常和异常的运动反应;2)确定最大摄氧量和残疾程度;3)确定导致呼吸困难和运动受限的因素;4)区分运动不耐受的呼吸(呼吸力学和肺气体交换)、心血管、代谢和外周肌肉原因;5)识别呼吸(呼吸力学和肺气体交换)、心血管和代谢系统以及外周肌肉和心理障碍的异常;6)筛查并存的缺血性心脏病、外周血管疾病和动脉低氧血症;7)协助制定个体化运动训练计划;8)提供预后信息;9)客观评估治疗干预的效果。因此,CPET 是患者临床评估的重要组成部分。本文属于针对临床医生、生理学家和研究人员的“心肺疾病通气效率及其临床预后价值”专题系列的一部分,旨在鼓励他们熟悉 CPET,以帮助和指导针对个体患者的临床决策。
Eur Respir Rev. 2021-3-31
Eur Respir Rev. 2021-12-31
Expert Rev Respir Med. 2024-6
Ann Am Thorac Soc. 2017-7
Expert Rev Respir Med. 2010-4
Cardiorenal Med. 2025
Biology (Basel). 2025-1-26
J Clin Med. 2024-4-12
Arch Bronconeumol (Engl Ed). 2020-9
Eur Respir Rev. 2019-12-18
Eur Respir J. 2019-6-13
PLoS One. 2018-8-10
Arch Bronconeumol. 2016-11-4
Respir Physiol Neurobiol. 2014-8-1